Roles of Clinical Laboratory Detection in Diagnosis and Treatment of Thyroid Nodule_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 郭林 , 王敏 , 卢仁泉

复旦大学附属肿瘤医院检验科（上海 200032）;

Corresponding author：

郭林, Email: guolin500@hotmail.Com

Keywords：

甲状腺结节; 实验室检查; 分子诊断

DOI：

10.7507/1007-9424.20140255

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 郭林, 王敏, 卢仁泉. Roles of Clinical Laboratory Detection in Diagnosis and Treatment of Thyroid Nodule. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2014, 21(9): 1056-1060. doi: 10.7507/1007-9424.20140255 Copy

1.	American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2009, 19(11):1167-1214.
2.	中华医学会内分泌学分会, 中华医学会外科学分会内分泌学组, 中国抗癌协会头颈肿瘤专业委员会, 等. 甲状腺结节和分化型甲状腺癌诊治指南[J]. 中华内分泌代谢杂志, 2012, 28(10):779-797.
3.	上海市疾病预防控制中心. 2009年上海市市区恶性肿瘤发病率[J]. 肿瘤, 2012, 32(10):854.
4.	Frates MC, Benson CB, Doubilet PM, et al. Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography[J]. J Clin Endocrinol Metab, 2006, 91(9):3411-3417.
5.	嵇庆海, 王玉龙, 郭智. 甲状腺癌诊治进展[J]. 肿瘤研究与临床, 2006, 18(3):214-216.
6.	Hamburger JI, Kaplan MM. Diagnosis of thyroid dysfunction in ambulatory patients:primacy of the supersensitive thyroidstimulating hormone assay[J]. Compr Ther, 1990, 16(7):3-7.
7.	Boelaert K, Horacek J, Holder RL, et al. Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration[J]. J Clin Endocrinol Metab, 2006, 91(11):4295-4301.
8.	Haymart MR, Repplinger DJ, Leverson GE, et al. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage[J]. J Clin Endocrinol Metab, 2008, 93(3):809-814.
9.	史良凤, 关海霞, 李玉姝, 等. 术前血清促甲状腺素水平与甲状腺结节良恶性关系的研究[J]. 中华内分泌代谢杂志, 2010, 26(3):213-214.
10.	NCCN. NCCN clinical practice guidelines in oncology (thyroid carcinoma). Version 1.2013[S]. NCCN, 2013:1-56.
11.	庄大勇. Tg与分化型甲状腺癌的研究进展[J]. 放射免疫学杂志, 2012, 25(5):532-535.
12.	Baker LJ, Gill AJ, Chan C, et al. Parasitic thyroid nodules:cancer or not?[J]. Endocrinol Diabetes Metab Case Rep, 2014, 2014:140027.
13.	高明. 甲状腺癌的诊疗进展及策略[J]. 中华耳鼻咽喉头颈外科杂志, 2010, 45(11):887-890.
14.	Camargo RY, Tomimori EK. Usefulness of ultrasound in the diagnosis and management of well-differentiated thyroid carcinoma[J]. Arq Bras Endocrinol Metabol, 2007, 51(5):783-792.
15.	Alzahrani AS, Mohamed G, Al Shammary A, et al. Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer[J]. J Endocrinol Invest, 2005, 28(6):540-546.
16.	赵勇, 陈波, 黄迅, 等. 促甲状腺素及甲状腺自身抗体水平与甲状腺结节良恶性的关系[J]. 中国现代医学杂志, 2012, 22(8):41-44.
17.	杨士军, 谭维琴, 刘满庆. TGA、TPOAb、TRAb测定对甲状腺疾病的诊断价值[J]. 放射免疫学杂志, 2008, 21(4):321-322.
18.	Spencer CA. Clinical review:clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC)[J]. J Clin Endocrinol Metab, 2011, 96(12):3615-3627.
19.	Larson SD, Jackson LN, Riall TS, et al. Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway[J]. J Am Coll Surg, 2007, 204(5):764-775.
20.	Santarpia L, Gagel RF, Sherman SI, et al. Diabetes insipidus and panhypopituitarism due to intrasellar metastasis from medullary thyroid cancer[J]. Head Neck, 2009, 31(3):419-423.
21.	薛声能, 雷娟, 李娜, 等. 降钙素和癌胚抗原联合检测在甲状腺髓样癌诊治中的意义[J]. 中国卫生检验杂志, 2012, 22(7):1620-1621, 1624.
22.	Roy M, Chen H, Sippel RS. Current understanding and management of medullary thyroid cancer[J]. Oncologist, 2013,18(10):1093-1100.
23.	Barbet J, Campion L, Kraeber-Bodéré F, et al. Prognostic impact of serum calcitonin and carcinoembryonic antigen doublingtimes in patients with medullary thyroid carcinoma[J]. J Clin Endocrinol Metab, 2005, 90(11):6077-6084.
24.	Caria P, Dettori T, Frau DV, et al. Assessing RET/PTC in thyroid nodule fine-needle aspirates:the FISH point of view[J]. Endocr Relat Cancer, 2013, 20(4):527-536.
25.	尹香利. BRAF基因与甲状腺癌临床及其预后关系的分子生物学研究[D]. 石河子:石河子大学, 2006.
26.	Kim MI, Alexander EK. Diagnostic use of molecular markers in the evaluation of thyroid nodules[J]. Endocr Pract, 2012, 18(5):796-802.
27.	Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement[J]. Cell, 1985, 42(2):581-588.
28.	Zou M, Baitei EY, Alzahrani AS, et al. Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma[J]. Thyroid, 2014,[Epub ahead of print].
29.	左庆瑶, 高燕明, 刘宝岳, 等. 乳头状甲状腺癌BRAFV600E突变的表达及意义[J]. 中华内科杂志, 2009, 48(5):412-413.
30.	Jang EK, Song DE, Sim SY, et al. NRAS codon 61 mutation is associated with distant metastasis in patients with follicular thyroid carcinoma[J]. Thyroid, 2014,[Epub ahead of print].
31.	Xing M. BRAF V600E mutation and papillary thyroid cancer[J]. JAMA, 2013, 310(5):535.
32.	Kroll TG, Sarraf P, Pecciarini L, et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma[corrected] [J]. Science, 2000, 289(5483):1357-1360.
33.	Asaad NY, Abd El-Wahed MM, Mohammed AG. Human telomerase reverse transcriptase (hTERT) gene expression in thyroid carcinoma:diagnostic and prognostic role[J]. J Egypt Natl Canc Inst, 2006, 18(1):8-16.
34.	Teng L, Specht MC, Barden CB, et al. Antisense hTERT inhibits thyroid cancer cell growth[J]. J Clin Endocrinol Metab, 2003, 88(3):1362-1366.
35.	Sugishita Y, Kammori M, Yamada O, et al. Biological differential diagnosis of follicular thyroid tumor and Hürthle cell tumor on the basis of telomere length and hTERT expression[J]. Ann Surg Oncol,2014,21(7):2318-2325.

1. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2009, 19(11):1167-1214.
2. 中华医学会内分泌学分会, 中华医学会外科学分会内分泌学组, 中国抗癌协会头颈肿瘤专业委员会, 等. 甲状腺结节和分化型甲状腺癌诊治指南[J]. 中华内分泌代谢杂志, 2012, 28(10):779-797.
3. 上海市疾病预防控制中心. 2009年上海市市区恶性肿瘤发病率[J]. 肿瘤, 2012, 32(10):854.
4. Frates MC, Benson CB, Doubilet PM, et al. Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography[J]. J Clin Endocrinol Metab, 2006, 91(9):3411-3417.
5. 嵇庆海, 王玉龙, 郭智. 甲状腺癌诊治进展[J]. 肿瘤研究与临床, 2006, 18(3):214-216.
6. Hamburger JI, Kaplan MM. Diagnosis of thyroid dysfunction in ambulatory patients:primacy of the supersensitive thyroidstimulating hormone assay[J]. Compr Ther, 1990, 16(7):3-7.
7. Boelaert K, Horacek J, Holder RL, et al. Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration[J]. J Clin Endocrinol Metab, 2006, 91(11):4295-4301.
8. Haymart MR, Repplinger DJ, Leverson GE, et al. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage[J]. J Clin Endocrinol Metab, 2008, 93(3):809-814.
9. 史良凤, 关海霞, 李玉姝, 等. 术前血清促甲状腺素水平与甲状腺结节良恶性关系的研究[J]. 中华内分泌代谢杂志, 2010, 26(3):213-214.
10. NCCN. NCCN clinical practice guidelines in oncology (thyroid carcinoma). Version 1.2013[S]. NCCN, 2013:1-56.
11. 庄大勇. Tg与分化型甲状腺癌的研究进展[J]. 放射免疫学杂志, 2012, 25(5):532-535.
12. Baker LJ, Gill AJ, Chan C, et al. Parasitic thyroid nodules:cancer or not?[J]. Endocrinol Diabetes Metab Case Rep, 2014, 2014:140027.
13. 高明. 甲状腺癌的诊疗进展及策略[J]. 中华耳鼻咽喉头颈外科杂志, 2010, 45(11):887-890.
14. Camargo RY, Tomimori EK. Usefulness of ultrasound in the diagnosis and management of well-differentiated thyroid carcinoma[J]. Arq Bras Endocrinol Metabol, 2007, 51(5):783-792.
15. Alzahrani AS, Mohamed G, Al Shammary A, et al. Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer[J]. J Endocrinol Invest, 2005, 28(6):540-546.
16. 赵勇, 陈波, 黄迅, 等. 促甲状腺素及甲状腺自身抗体水平与甲状腺结节良恶性的关系[J]. 中国现代医学杂志, 2012, 22(8):41-44.
17. 杨士军, 谭维琴, 刘满庆. TGA、TPOAb、TRAb测定对甲状腺疾病的诊断价值[J]. 放射免疫学杂志, 2008, 21(4):321-322.
18. Spencer CA. Clinical review:clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC)[J]. J Clin Endocrinol Metab, 2011, 96(12):3615-3627.
19. Larson SD, Jackson LN, Riall TS, et al. Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway[J]. J Am Coll Surg, 2007, 204(5):764-775.
20. Santarpia L, Gagel RF, Sherman SI, et al. Diabetes insipidus and panhypopituitarism due to intrasellar metastasis from medullary thyroid cancer[J]. Head Neck, 2009, 31(3):419-423.
21. 薛声能, 雷娟, 李娜, 等. 降钙素和癌胚抗原联合检测在甲状腺髓样癌诊治中的意义[J]. 中国卫生检验杂志, 2012, 22(7):1620-1621, 1624.
22. Roy M, Chen H, Sippel RS. Current understanding and management of medullary thyroid cancer[J]. Oncologist, 2013,18(10):1093-1100.
23. Barbet J, Campion L, Kraeber-Bodéré F, et al. Prognostic impact of serum calcitonin and carcinoembryonic antigen doublingtimes in patients with medullary thyroid carcinoma[J]. J Clin Endocrinol Metab, 2005, 90(11):6077-6084.
24. Caria P, Dettori T, Frau DV, et al. Assessing RET/PTC in thyroid nodule fine-needle aspirates:the FISH point of view[J]. Endocr Relat Cancer, 2013, 20(4):527-536.
25. 尹香利. BRAF基因与甲状腺癌临床及其预后关系的分子生物学研究[D]. 石河子:石河子大学, 2006.
26. Kim MI, Alexander EK. Diagnostic use of molecular markers in the evaluation of thyroid nodules[J]. Endocr Pract, 2012, 18(5):796-802.
27. Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement[J]. Cell, 1985, 42(2):581-588.
28. Zou M, Baitei EY, Alzahrani AS, et al. Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma[J]. Thyroid, 2014,[Epub ahead of print].
29. 左庆瑶, 高燕明, 刘宝岳, 等. 乳头状甲状腺癌BRAFV600E突变的表达及意义[J]. 中华内科杂志, 2009, 48(5):412-413.
30. Jang EK, Song DE, Sim SY, et al. NRAS codon 61 mutation is associated with distant metastasis in patients with follicular thyroid carcinoma[J]. Thyroid, 2014,[Epub ahead of print].
31. Xing M. BRAF V600E mutation and papillary thyroid cancer[J]. JAMA, 2013, 310(5):535.
32. Kroll TG, Sarraf P, Pecciarini L, et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma[corrected] [J]. Science, 2000, 289(5483):1357-1360.
33. Asaad NY, Abd El-Wahed MM, Mohammed AG. Human telomerase reverse transcriptase (hTERT) gene expression in thyroid carcinoma:diagnostic and prognostic role[J]. J Egypt Natl Canc Inst, 2006, 18(1):8-16.
34. Teng L, Specht MC, Barden CB, et al. Antisense hTERT inhibits thyroid cancer cell growth[J]. J Clin Endocrinol Metab, 2003, 88(3):1362-1366.
35. Sugishita Y, Kammori M, Yamada O, et al. Biological differential diagnosis of follicular thyroid tumor and Hürthle cell tumor on the basis of telomere length and hTERT expression[J]. Ann Surg Oncol,2014,21(7):2318-2325.

Previous Article
Diagnosis and Management of Thyroid Nodules in China
Next Article
Significance of Ultrasonographic Diagnosis in Thyroid Nodules

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Roles of Clinical Laboratory Detection in Diagnosis and Treatment of Thyroid Nodule

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content